Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS over expression

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 4, 2011, Pages

  Habibi, Javad ^a   DeMarco, Vincent G ^a   Ma, Lixin ^a   Pulakat, Lakshmi ^a,b   Rainey, William E ^c   Whaley Connell, Adam T ^a,b   Sowers, James R ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Aldosterone; Fibrosis; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID RECEPTOR; OXIDOREDUCTASE; PLACEBO; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE;

ARTICLE; BLOOD PRESSURE REGULATION; CINEANGIOCARDIOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DARK AGOUTI RAT; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE SEPTUM; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRANSGENIC RAT;

ALDOSTERONE ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; ENDOMYOCARDIAL FIBROSIS; MALE; NADPH OXIDASE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; TYROSINE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79955064277     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01000.2010     Document Type: Article

References (47)

1. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355-1364, 1990.
2. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26: 671-677, 1992.
3. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26: 809-820, 1994.
4. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45: 773-779, 2005.
5. De Angelis N, Fiordaliso F, Latini R, Calvillo L, Funicello M, Gobbi M, Mennini T, Masson S. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 34: 1655-1665, 2002.
6. DeMarco VG, Johnson MS, Habibi J, Pulakat L, Gul R, Hayden MR, Tilmon RD, Dellsperger KC, Winer N, Whaley-Connel AT, Sowers JR. Comparative analysis of telmisartan and olmesartan on cardiac function in the TG(mRen2)27 rat. Am J Physiol Heart Circ Physiol 300: H181-H190, 2011.
7. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC. Mineralocorticoid receptor affects AP-1 and nuclear factor-_B activation in angiotensin II-induced cardiac injury. Hypertension 37: 787-793, 2001.
8. Fouad FM, Slominski JM, Tarazi RC. Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function. J Am Coll Cardiol 3: 1500-1506, 1984.
9. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115: 1754-1761, 2007.
10. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20: 1546-1548, 2006.
11. Juliet PA, Hayashi T, Daigo S, Matsui-Hirai H, Miyazaki A, Fukatsu A, Funami J, Iguchi A, Ignarro LJ. Combined effect of testosterone and apocynin on nitric oxide and superoxide production in PMA-differentiated THP-1 cells. Biochim Biophys Acta 1693: 185-191, 2004.
12. Kapuku GK, Seto S, Mori H, Mori M, Utsunomia T, Suzuki S, Oku Y, Yano K, Hashiba K. Impaired left ventricular filling in borderline hypertensive patients without cardiac structural changes. Am Heart J 125: 1710-1716, 1993.
13. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109: 2213-2220, 2004.
14. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 47: 671-679, 2006.
15. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 111: 420-427, 2005.
16. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40: 477-484, 2002.
17. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, McDonald KM. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 54: 1674-1682, 2009.
18. Mohammed SF, Ohtani T, Korinek J, Lam CS, Larsen K, Simari RD, Valencik ML, Burnett JC Jr, Redfield MM. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation 122: 370-378, 2010.
19. Mureddu GF, Greco R, Rosato GF, Cella A, Vaccaro O, Contaldo F, de SG. Relation of insulin resistance to left ventricular hypertrophy and diastolic dysfunction in obesity. Int J Obes Relat Metab Disord 22: 363-368, 1998.
20. Nagano N, Nagano M, Yo Y, Iiyama K, Higaki J, Mikami H, Ogihara T. Role of glucose intolerance in cardiac diastolic function in essential hypertension. Hypertension 23: 1002-1005, 1994.
21. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47: 656-664, 2006.
22. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 292: R946-R954, 2007.
23. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355: 251-259, 2006.
24. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 313: 812-817, 2004.
25. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized ldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
27. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194-202, 2003.
28. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 33: 981-986, 1999.
29. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143: 4828-4836, 2002.
30. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283: H1802-H1810, 2002.
31. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283: H1802-H1810, 2002.
32. Rossi GP, Di B, V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 40: 23-27, 2002.
33. Sadoshima J, Izumo S. Molecular characterization of angiotensin II- induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413-423, 1993.
34. Sanchez-Mas J, Turpin MC, Lax A, Ruiperez JA, Valdes CM, Pascual-Figal DA. Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro. Rev Esp Cardiol 63: 779-787, 2010.
35. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 150: 776-783, 2009.
36. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, Qazi M, Morris EM, Cooper SA, Link CD, Stump C, Hay M, Ferrario C, Sowers JR. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of NADPH oxidase and cardiac remodeling. Endocrinology 148: 3773-3780, 2007.
37. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10: 97-107, 2002.
38. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosteroneinduced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161: 1773-1781, 2002.
39. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49: 241-248, 2007.
40. Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake Y, Takenaka K, Yatomi Y, Fujita T. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens 26: 1453-1462, 2008.
41. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15: 264-272, 2000.
42. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865, 1991.
43. Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, Hayden M, DeMarco V, Ferrario CM, Ibdah JA, Sowers JR. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation Hypertension 53: 158-165, 2009.
44. Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, Ma L, Qazi M, Link D, Karuparthi PR, Stump CS, Ferrario CM, Sowers JR. Angiotensin-II mediated oxidative stress promotes myocardial tissue remodeling in the transgenic TG (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab 293: E355-E363, 2007.
45. Whaley-Connell A, Habibi J, Cooper SA, DeMarco VG, Hayden MR, Stump CS, Link D, Ferrario C, Sowers JR. Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab 295: E103-E109, 2008.
46. Zhao W, Ahokas RA, Weber KT, Sun Y. ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol 291: H336-H343, 2006.
47. Zhou X, Ma L, Habibi J, Whaley-Connel AT, Hayden MR, Tilmon RD, Brown AN, DeMarco VG, Sowers JR. Nebivolol improves diastolic dysfunction and myocardial tissue remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 55: 880-888, 2009.